An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
Clinical trial NCT02658461 · COMPLETED
Trial details
- NCT number
- NCT02658461
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2012-02-01
- Primary completion
- 2013-02-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.